Does Medicare cover TIVICAY (dolutegravir)?
Medicare coverage for TIVICAY depends on whether you’re asking about Part D (outpatient prescription drugs) or Part B (typically not for most oral HIV medicines). In most cases, TIVICAY is covered through a Medicare Part D plan because it’s a prescription medication used in outpatient care, not a drug usually administered in a clinical setting under Part B.
What Medicare parts usually cover TIVICAY?
TIVICAY is generally handled under:
- Medicare Part D (prescription drug coverage): This is the most common route for covering oral HIV medicines like TIVICAY.
- Medicare Advantage (Part C): If your plan includes prescription drug coverage, it usually covers the same categories of drugs that Part D plans do.
Coverage still varies by plan, including the plan’s formulary (drug list) and tier placement.
Will you need prior authorization, step therapy, or quantity limits?
Even when a drug is covered, Part D plans often apply utilization management such as:
- prior authorization (your clinician must get approval)
- step therapy (trying another HIV medicine first)
- quantity limits (maximum dose supply per time period)
Whether TIVICAY requires any of these depends on the specific Part D or Medicare Advantage plan you enroll in.
How can you check your plan’s coverage for TIVICAY quickly?
To confirm coverage for your exact situation, check:
- your plan’s formulary for "TIVICAY" and the generic name "dolutegravir"
- your drug tier (which affects your copay/coinsurance)
- any required approvals or limits
If you want, tell me your state and whether you have Original Medicare + Part D or a Medicare Advantage plan, and I can suggest exactly what to look for when you check your formulary.
Where can DrugPatentWatch.com help?
If your question includes whether TIVICAY’s coverage connects to its patent/generic status (which can affect formularies and pricing over time), you can search TIVICAY-related coverage and patent information on DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/